羚锐品牌怎么样 申请店铺

我要投票 羚锐在中草药行业中的票数:891 更新时间:2026-01-09
羚锐是哪个国家的品牌?「羚锐」是 河南羚锐制药股份有限公司 旗下著名品牌。该品牌发源于河南,由创始人熊伟在1999-04-18期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力羚锐品牌出海!将品牌入驻外推网,定制羚锐品牌推广信息,可以显著提高羚锐产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

羚锐怎么样

河南羚锐制药股份有限公司始创于1992年6月,由河南省信阳羚羊山制药厂和香港锐星企业公司合资组建而成,2000年10月成功上市,成长为国内知名制药企业。目前,公司在北京、上海、武汉、郑州、信阳等地控股、参股十余家企业,拥有多个科研、生产基地,其中羚锐新县生态工业园为国内最大的橡胶膏剂药品生产基地,羚锐信阳科技园为国内先进的大型口服药生产基地,建立在北京的羚锐药物研究院和羚锐伟业科技有限公司为公司的科技研发基地。公司资产总额10亿元,年创利税逾亿元,已成为当地经济发展的支柱企业。

公司拥有橡胶膏剂、片剂、胶囊剂、颗粒剂、酊剂等十大剂型百余种产品,其中包括通络祛痛膏(骨质增生一贴灵)、培元通脑胶囊、丹鹿通督片、胃疼宁片、参芪降糖胶囊等独家拥有知识产权的产品及国家中药保护品种和国家医保药品。公司的所有产品剂型及其生产车间均通过国家GMP认证,质量标准实现了与国际接轨。

公司先后被评为“全国中药工业50强企业”、“全国中药系统先进集体”、“全国医药优秀企业”、“国家知识产权试点单位”,1999年和2005年先后两次被中央文明委表彰为“全国精神文明建设工作先进单位”,2001年被国家科技部认定为“国家火炬计划重点高新技术企业”,公司党委被中组部命名表彰为“全国先进基层党组织”;2002年“羚锐”商标被国家工商行政管理总局认定为“中国驰名商标”,成为国内橡胶膏剂药业中首件驰名商标。藉此,羚锐制药被业界誉为“中国橡胶膏剂药业第一品牌”。

浴火淬炼,十数年磨剑,羚锐始崛起,并稳健前进。

以“诚信立业,造福人类”为本,弘“团结、进取、创新、奉献”之志,坚持创新,实施人才兴企战略,以高新技术与传统药理、现代理念与先进文化完美融合,构筑企业平台,共享发展资源,我们将进一步提升核心竞争力,着力打造医药的优秀企业,成就百年基业。

Henan Lingrui Pharmaceutical Co., Ltd. was founded in June 1992 by Henan Xinyang lingyangshan pharmaceutical factory and Hong Kong Ruixing enterprise company. It was successfully listed in October 2000 and grew into a well-known pharmaceutical enterprise in China. At present, the company holds and shares more than ten enterprises in Beijing, Shanghai, Wuhan, Zhengzhou, Xinyang and other places, and has many scientific research and production bases. Among them, Lingrui new County Ecological Industrial Park is the largest rubber paste drug production base in China, Lingrui Xinyang science and technology park is the advanced large oral drug production base in China, and Lingrui Drug Research Institute and Lingrui Weiye science and technology established in Beijing Ltd. is the R & D base of the company. The company has a total assets of 1 billion yuan and an annual income tax of more than 100 million yuan, which has become a pillar enterprise of local economic development. The company has more than 100 kinds of products in ten dosage forms including rubber plaster, tablet, capsule, granule and tincture, including Tongluo Qutong plaster (hyperosteogeny Yitieling), Peiyuan Tongnao capsule, Danlu Tongdu tablet, Weitongning tablet, Shenqi Jiangtang Capsule and other products with exclusive intellectual property rights, national traditional Chinese medicine protection varieties and national medical insurance drugs. All the dosage forms and production workshops of the company have passed the national GMP certification, and the quality standards have been in line with the international standards. The company has been awarded as "top 50 enterprises of Chinese medicine industry", "advanced collective of Chinese medicine system", "excellent enterprise of Chinese medicine" and "pilot unit of national intellectual property". In 1999 and 2005, the company was awarded as "advanced unit of national spiritual civilization construction" by the central civilization Committee. In 2001, the company was recognized as "key high and new technology of national Torch Plan" by the Ministry of science and technology In 2002, "Lingrui" trademark was recognized as "China's well-known trademark" by the State Administration for Industry and commerce, and became the first well-known trademark in the domestic rubber paste pharmaceutical industry. Therefore, Lingrui pharmaceutical is known as "the first brand of Chinese rubber paste pharmaceutical industry". Bath fire quenching, more than ten years of sword sharpening, antelope sharp began to rise, and steady progress. Based on the principle of "building a business in good faith and benefiting mankind", we will carry out the strategy of "uniting, enterprising, innovating and dedicating", persist in innovation, carry out the strategy of developing an enterprise with talents, perfectly integrate high and new technology with traditional pharmacology, modern concept and advanced culture, build an enterprise platform and share development resources. We will further enhance our core competitiveness and strive to build an excellent enterprise in medicine, Achieve a century long foundation.

本文链接: https://brand.waitui.com/e8963bc9e.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

华纳兄弟探索公司拒绝派拉蒙,坚持与Netflix的交易

华纳兄弟探索公司敦促股东拒绝派拉蒙的敌意收购,并重申其将工作室和流媒体资产出售给Netflix的协议是更优报价,且完成路径更明确。(新浪财经)

2小时前

Grok因涉性图像面临审查

埃隆·马斯克麾下未上市企业xAI在其Grok模型被用于生成涉性图像(包括未成年人图像)后受到抨击,这引发了监管机构对该与X平台集成的工具的调查和政策质疑。(新浪财经)

2小时前

保险公司发债规模连续三年超千亿元,多重因素推动

连续三年,保险公司发行债券规模超千亿元。刚刚过去的2025年,23家保险公司发债规模合计达1042亿元。业内人士普遍认为,这背后有多重推动因素——低利率周期下,保险公司普遍面临较高的资本补充需求;利率下行,发债成本更低,险企有动力发新债置换旧债;也有险企希望在利率低位时融资以进一步夯实资本实力、增厚发展安全垫。另外,在逆周期监管思路下,保险公司发债也在一定程度上获得了监管部门的支持。(证券时报)

2小时前

中信建投:白酒板块迎来周期底部配置机会

36氪获悉,中信建投指出,白酒产业“五底阶段”(政策底、库存底、动销底、批价底、产销底)与资本市场“三低一高”(预期低、估值低、公募持仓低、高分红)共振,结合近期市场策略相继落地,站在春节旺季来临之际,认为本轮白酒调整期拐点将至,资本市场预期先行,白酒板块迎来周期底部配置机会。

2小时前

CrowdStrike以7.4亿美元收购身份安全初创公司SGNL

网络安全提供商CrowdStrike周四宣布,将以近7.4亿美元的价格收购身份管理初创公司SGNL,以在人工智能网络攻击时代加强防御。该公司表示,此次收购将帮助CrowdStrike的Falcon云安全平台用户更好地管理人员和人工智能身份访问请求以及实时风险。该交易预计将于2027财年第一季度完成。(新浪财经)

2小时前

本页详细列出关于羚锐的品牌信息,含品牌所属公司介绍,羚锐所处行业的品牌地位及优势。
咨询